We are live on ! Find out more
VKTX icon

Viking Therapeutics
VKTX

33 hedge funds and large institutions have $37.9M invested in Viking Therapeutics in 2017 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

885% more capital invested

Capital invested by funds: $3.85M → $37.9M (+$34.1M)

700% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 1

214% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 7

83% more funds holding

Funds holding: 18 → 33 (+15)

19.34% more ownership

Funds ownership: 7.3% → 26.64% (+19%)

Holders
33
Holders Change
+15
Holders Change %
+83.33%
% of All Funds
0.75%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
22
Increased
8
Reduced
1
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
+$5.39M
2
SCM
Sio Capital Management
New York
+$3.63M
3
Millennium Management
Millennium Management
New York
+$2.04M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.88M
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.45M

Top Sellers

Rank Fund Capital Flow
1
AC
Ascend Capital
California
-$932K
2
SKK
Shepherd Kaplan Krochuk
Massachusetts
-$180K
3
Citadel Advisors
Citadel Advisors
Florida
-$108K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$98K
5
VF
Virtu Financial
New York
-$70K
Name Holding Trade Value Shares
Change 		Change in
Stake
Parallax Volatility Advisers
26
Parallax Volatility Advisers
California
$30K +$21.7K +7,474 New
Fifth Third Bancorp
27
Fifth Third Bancorp
Ohio
$21K +$15.2K +5,250 New
Royal Bank of Canada
28
Royal Bank of Canada
Ontario, Canada
$12K +$8.71K +3,000 +300,000%
Macquarie Group
29
Macquarie Group
Australia
$9K +$6.1K +2,100 New
Deutsche Bank
30
Deutsche Bank
Germany
$9K +$6.68K +2,300 New
Barclays
31
Barclays
United Kingdom
$7K +$4.89K +1,685 New
RFA
32
Reilly Financial Advisors
California
$5K – – –
BlackRock
33
BlackRock
New York
$3K – – –
AC
34
Ascend Capital
California
– -$932K -488,208 Closed
Citadel Advisors
35
Citadel Advisors
Florida
– -$108K -56,461 Closed
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
– -$98K -51,247 Closed
VF
37
Virtu Financial
New York
– -$70K -36,588 Closed
TSS
38
Two Sigma Securities
New York
– -$22K -11,481 Closed
GC
39
Guggenheim Capital
Illinois
– -$20K -10,366 Closed
AG
40
Advisor Group
Arizona
– -$1K -500 Closed
1
2

VKTX Hedge Fund Activity: Q4 2017 in Review

33 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q4 2017, worth a combined $37.9M — up 885% from $3.85M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new VKTX positions and 7 closed out — a net gain of 15 holders — while 8 added to existing stakes and 1 trimmed.

The largest buyer was Sphera Funds Management, adding an estimated $5.39M. The largest seller was Ascend Capital, exiting entirely with an estimated $932K sold.

  • 33 institutional investors held Viking Therapeutics (VKTX) as of Q4 2017, up from 18 in Q3 2017.
  • Funds reported $37.9M of Viking Therapeutics stock for Q4 2017, up 885% quarter-over-quarter.
  • 22 funds opened new Viking Therapeutics positions in Q4 2017 and 7 closed out, a net change of +15 holders.
  • The largest Viking Therapeutics buyer in Q4 2017 was Sphera Funds Management, an estimated $5.39M added.
  • The largest Viking Therapeutics seller in Q4 2017 was Ascend Capital, an estimated $932K sold.

Based on aggregated 13F filings for Q4 2017.